CClinicalTrials.gg
Sign In
CompletedNCT03014167Updated Jan 22, 2026Results posted

Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)

A Phase 3 interventional study of Albendazole in Helminthiasis and Filariasis, sponsored by University of Washington. Completed at 3 sites in 3 countries. Open to participants aged 12 Months and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by University of Washington · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
357,716
Allocation
Randomized
Ages
12 Months and older
Sex
All
01

Study summary

Over 1.5 billion people are infected with soil-transmitted helminths (STH). Global STH guidelines recommend MDA (mass drug administration) of albendazole or mebendazole to targeted populations, including pre-school age children and school-age children. However mathematical models suggests that current MDA strategies are not sufficient for interrupting disease transmission in most areas. Meanwhile many lymphatic filariasis (LF) programs have successfully treated entire populations with albendazole (in combination with ivermectin or diethylcarbamazine) and are transitioning to a state of post-MDA surveillance. This project will conduct a series of community-based cluster randomized trials in India, Malawi, and Benin to determine if maintaining three years of MDA with albendazole to entire communities following the cessation of LF programs can interrupt STH transmission in focal geographic areas. Additionally, this study aims to compare the efficacy of community-wide MDA versus targeted MDA of children in interrupting the transmission of STH. Nested implementation science research will be used to optimize the intervention, identify contextual factors influencing trial efficacy, and evaluate the feasibility of sustaining and scaling community-wide MDA for STH. These data will provide evidence necessary to inform future guidelines, policies, and operational plans as country partners engage in intensified approaches to eliminate these disabling diseases.

02

Conditions studied

  • Helminthiasis
  • Filariasis

Keywords

  • transmission interruption
  • intestinal nematodes
  • soil-transmitted helminths
  • mass drug administration
  • Benin
  • India
  • Malawi
03

Who can participate

Ages eligible
12 Months and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Treatment Inclusion Criteria:

  • Ages 12 months and older

Treatment Exclusion Criteria:

  • Children under 12 months of age
  • Pregnant women in their first trimester
  • History of adverse reaction to benzimidazoles

Outcome Sampling Inclusion Criteria:

  • Resident of study clusters
  • Ages 12 months and older
  • Willingness of adult aged 18 years and above (or age as per country specific ethical guidelines) or parent/guardian of child to provide written informed consent
  • Provision of written assent to participate from children aged 8 years and above (or age as per country specific ethical guidelines)

Outcome Sampling Exclusion Criteria:

  • Less than 12 months of age
  • Individuals who do not typically reside in the study cluster
  • Nonconsenting or assenting individuals, as applicable
04

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
357,716 participants (actual)

Study arms

  • Experimental
    Community-wide deworming

    Twice-yearly community-wide treatment delivered by drug distributors door to door or via community gatherings, depending upon the format of the prior LF program, for three years. All individuals above the age of 12 months will receive a single dose of albendazole.

    Drug: Albendazole

  • Active comparator
    Targeted deworming

    Pre-school (pre-SAC) and school-age children (SAC) 12 months of age and older will receive albendazole delivered in accordance with national Ministry of Health guidelines for three years.

    Drug: Albendazole

Interventions

  • DrugAlbendazole

    All eligible individuals will receive a single dose of 400 mg albendazole.

    Also known as: Albenza

05

What researchers measure

Primary outcomes

  1. Comparison of Arms - Benin

    Individual-level soil-transmitted helminth species-specific endline quantitative PCR prevalence

    Time frame: 5 years (Three years of drug administration and two years of surveillance)

  2. Comparison of Arms - India

    Individual-level soil-transmitted helminth species-specific endline quantitative PCR prevalence

    Time frame: 5 years (Three years of drug administration and two years of surveillance)

  3. Comparison of Arms - Malawi

    Individual-level soil-transmitted helminth species-specific endline quantitative PCR prevalence

    Time frame: 5 years (Three years of drug administration and two years of surveillance)

  4. N. Americanus Transmission Interruption - Benin

    Prevalence of N. americanus infection ≤2% 24 months following the final round of mass drug administration with albendazole

    Time frame: 5 years (Three years of drug administration and two years of surveillance)

  5. N. Americanus Transmission Interruption - India

    Prevalence of N. americanus infection ≤2% 24 months following the final round of mass drug administration with albendazole

    Time frame: 5 years (Three years of drug administration and two years of surveillance)

  6. N. Americanus Transmission Interruption - Malawi

    Prevalence of N. americanus infection ≤2% 24 months following the final round of mass drug administration with albendazole

    Time frame: 5 years (Three years of drug administration and two years of surveillance)

Secondary outcomes

  1. N. Americanus Transmission Interruption - Pooled

    Prevalence of N. americanus infection ≤2% 24 months following the final round of mass drug administration with albendazole

    Time frame: 5 years (Three years of drug administration and two years of surveillance)

  2. Comparison of Arms - Pooled

    Individual-level soil-transmitted helminth species-specific endline quantitative PCR prevalence

    Time frame: 5 years (Three years of drug administration and two years of surveillance)

  3. STH Transmission Interruption - Pooled

    Prevalence of STH infection ≤2% 24 months following the final round of mass drug administration with albendazole

    Time frame: 5 years (Three years of drug administration and two years of surveillance)

  4. STH Transmission Interruption - Benin

    Prevalence of STH infection ≤2% 24 months following the final round of mass drug administration with albendazole

    Time frame: 5 years (Three years of drug administration and two years of surveillance)

  5. STH Transmission Interruption - India

    Prevalence of STH infection ≤2% 24 months following the final round of mass drug administration with albendazole

    Time frame: 5 years (Three years of drug administration and two years of surveillance)

  6. STH Transmission Interruption - Malawi

    Prevalence of STH infection ≤2% 24 months following the final round of mass drug administration with albendazole

    Time frame: 5 years (Three years of drug administration and two years of surveillance)

06

Results

Posted Jan 22, 2026

Participant flow

All participants were approached during a baseline census and offered the opportunity to participant in the study. Consent was taken from an adult household member for the entire household.

Participant flow — Overall Study
MilestoneCommunity-wide Deworming (Intervention)School-age-targeted Deworming (Control)
Started177705179207
Completed119342116665
Not completed5836362542

Outcome measures

SecondaryN. Americanus Transmission Interruption - Pooled

Prevalence of N. americanus infection ≤2% 24 months following the final round of mass drug administration with albendazole

Time frame:
5 years (Three years of drug administration and two years of surveillance)
Reported as:
Count of units · Study clusters
N. Americanus Transmission Interruption - Pooled
Study clustersCommunity-wide Deworming (Intervention)School-age-targeted Deworming (Control)
Transmission interruption126
Did not achieve transmission interruption4854
SecondaryComparison of Arms - Pooled

Individual-level soil-transmitted helminth species-specific endline quantitative PCR prevalence

Time frame:
5 years (Three years of drug administration and two years of surveillance)
Reported as:
Count of participants · Participants
Comparison of Arms - Pooled
ParticipantsCommunity-wide Deworming (Intervention)School-age-targeted Deworming (Control)
N. americanus (primary)3055 (0.36 to 0.48)7047
A. duodenale20 (0.33 to 1.51)29
A. lumbricoides152 (0.89 to 2.18)81
T. trichiura22 (0.76 to 3.12)15
Any STH species3243 (0.37 to 0.49)7153
PrimaryComparison of Arms - Benin

Individual-level soil-transmitted helminth species-specific endline quantitative PCR prevalence

Time frame:
5 years (Three years of drug administration and two years of surveillance)
Reported as:
Count of participants · Participants
Comparison of Arms - Benin
ParticipantsCommunity-wide Deworming (Intervention)School-age-targeted Deworming (Control)
N. americanus — N americanus322748
A duodenale — N americanus1111
A lumbricoides — N americanus12359
T trichiura — N americanus136
Any STH species — N americanus467819
PrimaryComparison of Arms - India

Individual-level soil-transmitted helminth species-specific endline quantitative PCR prevalence

Time frame:
5 years (Three years of drug administration and two years of surveillance)
Reported as:
Count of participants · Participants
Comparison of Arms - India
ParticipantsCommunity-wide Deworming (Intervention)School-age-targeted Deworming (Control)
N. americanus (primary)1906 (0.32 to 0.52)4310
A. duodenale3 (0.17 to 4.94)3
A. lumbricoides17 (0.81 to 5.29)7
T. trichiura7 (0.34 to 2.67)5
Any STH species1930 (0.33 to 0.52)4318 (na to na)
PrimaryComparison of Arms - Malawi

Individual-level soil-transmitted helminth species-specific endline quantitative PCR prevalence

Time frame:
5 years (Three years of drug administration and two years of surveillance)
Reported as:
Count of participants · Participants
Comparison of Arms - Malawi
ParticipantsCommunity-wide Deworming (Intervention)School-age-targeted Deworming (Control)
N. americanus (primary)827 (0.34 to 0.46)1989 (na to na)
A. duodenale6 (0.07 to 1.40)15 (na to na)
A. lumbricoides12 (0.37 to 1.38)15 (na to na)
T. trichiura2 (0.03 to 2.63)4 (na to na)
Any STH species846 (0.35 to 0.47)2016 (na to na)
PrimaryN. Americanus Transmission Interruption - Benin

Prevalence of N. americanus infection ≤2% 24 months following the final round of mass drug administration with albendazole

Time frame:
5 years (Three years of drug administration and two years of surveillance)
Reported as:
Count of units · Study clusters
N. Americanus Transmission Interruption - Benin
Study clustersCommunity-wide Deworming (Intervention)School-age-targeted Deworming (Control)
Transmission interruption116
Did not achieve transmission interruption914
PrimaryN. Americanus Transmission Interruption - India

Prevalence of N. americanus infection ≤2% 24 months following the final round of mass drug administration with albendazole

Time frame:
5 years (Three years of drug administration and two years of surveillance)
Reported as:
Count of units · Study clusters
N. Americanus Transmission Interruption - India
Study clustersCommunity-wide Deworming (Intervention)School-age-targeted Deworming (Control)
Transmission interruption10
Did not achieve transmission interruption1920
SecondarySTH Transmission Interruption - Pooled

Prevalence of STH infection ≤2% 24 months following the final round of mass drug administration with albendazole

Time frame:
5 years (Three years of drug administration and two years of surveillance)
Reported as:
Count of units · Study clusters
STH Transmission Interruption - Pooled
Study clustersCommunity-wide Deworming (Intervention)School-age-targeted Deworming (Control)
Transmission interruption95
Did not achieve transmission interruption5155
SecondarySTH Transmission Interruption - Benin

Prevalence of STH infection ≤2% 24 months following the final round of mass drug administration with albendazole

Time frame:
5 years (Three years of drug administration and two years of surveillance)
Reported as:
Count of units · Study clusters
STH Transmission Interruption - Benin
Study clustersCommunity-wide Deworming (Intervention)School-age-targeted Deworming (Control)
Transmission interruption95
Did not achieve transmission interruption1115
SecondarySTH Transmission Interruption - India

Prevalence of STH infection ≤2% 24 months following the final round of mass drug administration with albendazole

Time frame:
5 years (Three years of drug administration and two years of surveillance)
Reported as:
Count of units · Study clusters
STH Transmission Interruption - India
Study clustersCommunity-wide Deworming (Intervention)School-age-targeted Deworming (Control)
Transmission interruption00
Did not achieve transmission interruption2020
SecondarySTH Transmission Interruption - Malawi

Prevalence of STH infection ≤2% 24 months following the final round of mass drug administration with albendazole

Time frame:
5 years (Three years of drug administration and two years of surveillance)
Reported as:
Count of units · Study clusters
STH Transmission Interruption - Malawi
Study clustersCommunity-wide Deworming (Intervention)School-age-targeted Deworming (Control)
Transmission interruption00
Did not achieve transmission interruption2020
PrimaryN. Americanus Transmission Interruption - Malawi

Prevalence of N. americanus infection ≤2% 24 months following the final round of mass drug administration with albendazole

Time frame:
5 years (Three years of drug administration and two years of surveillance)
Reported as:
Count of units · Study clusters
N. Americanus Transmission Interruption - Malawi
Study clustersCommunity-wide Deworming (Intervention)School-age-targeted Deworming (Control)
Transmission interruption00
Did not achieve transmission interruption2020

Adverse events

Collected over 2 years, 9 months. Treatment with albendazole is known to be safe and billions of doses have been distributed over the previous decades. Therefore, a comparison between arms was not an objective of the study and adverse events were only collected to reduce the risk of harm to research subjects. Therefore, adverse events were passively ascertained during rounds of mass drug administration contacted the study staff and a study clinician reviewed and responded to adverse events.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Community-wide Deworming (Intervention)0/242,344 (0%)13/242,344 (0%)0/242,344 (0%)
Most frequent serious events
Most frequent serious events
EventCommunity-wide Deworming (Intervention)
FaintingGeneral disorders4/242344
Fever / malariaInfections and infestations4/242344
Acute gastroenteritisGastrointestinal disorders3/242344
Viral feverGastrointestinal disorders1/242344
Impacted bowelGastrointestinal disorders1/242344

Baseline characteristics

Censused population prior to the intervention

Age, Customized
Age, Customized(Participants)Community-wide Deworming (Intervention)School-age-targeted Deworming (Control)Total
Age category — Infants (<1 year)433743968733
Age category — Pre-school-age children (1-4 years)184911863437125
Age category — School-age children (5-14 years)424714306285533
Age category — Adults (15+ years)112284113618225902
Age category — Unknown122301423
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Community-wide Deworming (Intervention)School-age-targeted Deworming (Control)Total
Sex — Male8623387430173663
Sex — Female9146692564184030
Sex — Other61723
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Community-wide Deworming (Intervention)School-age-targeted Deworming (Control)Total
Language — Majority language168000169596337596
Language — Minority Language7334814915483
Language — Unknown237122664637
Region of Enrollment
Region of Enrollment(participants)Community-wide Deworming (Intervention)School-age-targeted Deworming (Control)Total
Benin482414672894969
Malawi6100760811121818
India6845772472141929
Baseline STH prevalence: qPCR
Baseline STH prevalence: qPCR(Participants)Community-wide Deworming (Intervention)School-age-targeted Deworming (Control)Total
N. americanus228822144502
A. lumbricoides141148289
A. duodenale231740
T. trichiura231942
Any STH species244423684812
07

Study locations

3 sites
  • Institut de Recherche pour le Développement
    Comé, Benin
  • Christian Medical College
    Vellore, India
  • London School of Hygiene and Tropical Medicine
    Mangochi, Malawi
08

References and documents

Publications

  • Ajjampur SSR, Aruldas K, Asbjornsdottir KH, Avokpaho E, Bailey R, Cottrell G, Galagan SR, Halliday KE, Houngbegnon P, Ibikounle M, Israel GJ, Kaliappan SP, Kalua K, Legge H, Littlewood DTJ, Luty AJF, Manuel M, Massougbodji A, Means AR, Oswald WE, Pilotte N, Pullan R, Ramesh RM, Samikwa L, Simwanza J, Thomas KK, Williams SA, Witek-McManus S, Walson JL; DeWorm3 Trials Team. Feasibility of interrupting the transmission of soil-transmitted helminths: the DeWorm3 community cluster-randomised controlled trial in Benin, India, and Malawi. Lancet. 2025 Aug 2;406(10502):475-488. doi: 10.1016/S0140-6736(25)00766-4. PubMed 40752908 ↗
  • Means AR, Asbjornsdottir KH, Sharrock KC, Galagan SR, Aruldas K, Avokpaho E, Chabi F, Halliday KE, Houngbegnon P, Israel GJ, Kaliappan SP, Kennedy D, Legge H, Oswald WE, Palanisamy G, Rogers E, Timothy J, Pearman E, Ramesh RM, Simwanza J, Sheik-Abdullah JF, Sheikh M, Togbevi CI, Witek-McManus S, Pullan RL, Bailey R, Kalua K, Ibikounle M, Luty AJF, Ajjampur SSR, Walson JL. Coverage of community-wide mass drug administration platforms for soil-transmitted helminths in Benin, India, and Malawi: findings from the DeWorm3 project. Infect Dis Poverty. 2024 Oct 8;13(1):72. doi: 10.1186/s40249-024-01241-0. PubMed 39380086 ↗
  • Witek-McManus S, Simwanza J, Msiska R, Mangawah H, Oswald W, Timothy J, Galagan S, Pearman E, Shaikh M, Legge H, Walson J, Juziwelo L, Davey C, Pullan R, Bailey RL, Kalua K, Kuper H. Disability in childhood and the equity of health services: a cross-sectional comparison of mass drug administration strategies for soil-transmitted helminths in southern Malawi. BMJ Open. 2024 Sep 5;14(9):e083321. doi: 10.1136/bmjopen-2023-083321. PubMed 39242171 ↗
  • Saxena M, Roll A, Walson JL, Pearman E, Legge H, Nindi P, Chirambo CM, Titus A, Johnson J, Belou EA, Togbevi CI, Chabi F, Avokpaho E, Kalua K, Ajjampur SSR, Ibikounle M, Aruldas K, Means AR. "Our desire is to make this village intestinal worm free": Identifying determinants of high coverage of community-wide mass drug administration for soil transmitted helminths in Benin, India, and Malawi. PLoS Negl Trop Dis. 2024 Feb 6;18(2):e0011819. doi: 10.1371/journal.pntd.0011819. eCollection 2024 Feb. PubMed 38319937 ↗
  • Kazura E, Johnson J, Morozoff C, Aruldas K, Avokpaho E, Togbevi CI, Chabi F, Gwayi-Chore MC, Nindi P, Titus A, Houngbegnon P, Kaliappan SP, Jacob Y, Simwanza J, Kalua K, Walson JL, Ibikounle M, Ajjampur SSR, Means AR. Identifying opportunities to optimize mass drug administration for soil-transmitted helminths: A visualization and descriptive analysis using process mapping. PLoS Negl Trop Dis. 2024 Jan 4;18(1):e0011772. doi: 10.1371/journal.pntd.0011772. eCollection 2024 Jan. PubMed 38175837 ↗
  • Ramesh RM, Oswald WE, Israel GJ, Aruldas K, Galagan S, Legge H, Puthupalayam Kaliappan S, Walson J, Halliday KE, Ajjampur SSR. Representativeness of a mobile phone-based coverage evaluation survey following mass drug administration for soil-transmitted helminths: a comparison of participation between two cross-sectional surveys. BMJ Open. 2023 Oct 29;13(10):e070077. doi: 10.1136/bmjopen-2022-070077. PubMed 37899143 ↗
  • Sheahan W, Anderson R, Aruldas K, Avokpaho E, Galagan S, Goodman J, Houngbegnon P, Israel GJ, Janagaraj V, Kaliappan SP, Means AR, Morozoff C, Pearman E, Ramesh RM, Roll A, Schaefer A, Simwanza J, Witek-McManus S, Ajjampur SSR, Bailey R, Ibikounle M, Kalua K, Luty AJF, Pullan R, Walson JL, Asbjornsdottir KH. Overestimation of school-based deworming coverage resulting from school-based reporting. PLoS Negl Trop Dis. 2023 Apr 10;17(4):e0010401. doi: 10.1371/journal.pntd.0010401. eCollection 2023 Apr. PubMed 37036890 ↗
  • Aruldas K, Israel GJ, Johnson J, Titus A, Saxena M, Kaliappan SP, Ramesh RM, Walson JL, Means AR, Ajjampur SSR. Impact of adverse events during community-wide mass drug administration for soil-transmitted helminths on subsequent participation-a Theory of Planned Behaviour analysis. PLoS Negl Trop Dis. 2023 Mar 14;17(3):e0011148. doi: 10.1371/journal.pntd.0011148. eCollection 2023 Mar. PubMed 36917597 ↗
  • Aruldas K, Dawson K, Saxena M, Titus A, Johnson J, Gwayi-Chore MC, Muliyil J, Kang G, Walson JL, Khera A, Ajjampur SSR, Means AR. Evaluation of opportunities to implement community-wide mass drug administration for interrupting transmission of soil-transmitted helminths infections in India. PLoS Negl Trop Dis. 2023 Mar 10;17(3):e0011176. doi: 10.1371/journal.pntd.0011176. eCollection 2023 Mar. PubMed 36897877 ↗
  • Roll A, Saxena M, Orlan E, Titus A, Juvekar SK, Gwayi-Chore MC, Avokpaho E, Chabi F, Togbevi CI, Belou Elijan A, Nindi P, Walson JL, Ajjampur SSR, Ibikounle M, Kalua K, Aruldas K, Means AR. Policy stakeholder perspectives on barriers and facilitators to launching a community-wide mass drug administration program for soil-transmitted helminths. Glob Health Res Policy. 2022 Dec 2;7(1):47. doi: 10.1186/s41256-022-00281-z. PubMed 36461087 ↗
  • Morozoff C, Avokpaho E, Puthupalayam Kaliappan S, Simwanza J, Gideon SP, Lungu W, Houngbegnon P, Galactionova K, Sahu M, Kalua K, Luty AJF, Ibikounle M, Bailey R, Pullan R, Ajjampur SSR, Walson J, Means AR. Costs of community-wide mass drug administration and school-based deworming for soil-transmitted helminths: evidence from a randomised controlled trial in Benin, India and Malawi. BMJ Open. 2022 Jul 8;12(7):e059565. doi: 10.1136/bmjopen-2021-059565. PubMed 35803632 ↗
  • Avokpaho E, Lawrence S, Roll A, Titus A, Jacob Y, Puthupalayam Kaliappan S, Gwayi-Chore MC, Chabi F, Togbevi CI, Elijan AB, Nindi P, Walson JL, Ajjampur SSR, Ibikounle M, Kalua K, Aruldas K, Means AR. It depends on how you tell: a qualitative diagnostic analysis of the implementation climate for community-wide mass drug administration for soil-transmitted helminth. BMJ Open. 2022 Jun 14;12(6):e061682. doi: 10.1136/bmjopen-2022-061682. PubMed 35701056 ↗
  • Avokpaho EFGA, Houngbegnon P, Accrombessi M, Atindegla E, Yard E, Rubin Means A, Kennedy DS, Littlewood DTJ, Garcia A, Massougbodji A, Galagan SR, Walson JL, Cottrell G, Ibikounle M, Asbjornsdottir KH, Luty AJF. Factors associated with soil-transmitted helminths infection in Benin: Findings from the DeWorm3 study. PLoS Negl Trop Dis. 2021 Aug 17;15(8):e0009646. doi: 10.1371/journal.pntd.0009646. eCollection 2021 Aug. PubMed 34403424 ↗
  • Means AR, Orlan E, Gwayi-Chore MC, Titus A, Kaliappan SP, Togbevi CI, Chabi F, Halliday KE, Nindi P, Avokpaho E, Kalua K, Ibikounle M, Ajjampur SSR, Weiner BJ, Walson JL, Aruldas K. Structural readiness to implement community-wide mass drug administration programs for soil-transmitted helminth elimination: results from a three-country hybrid study. Implement Sci Commun. 2021 Jul 19;2(1):80. doi: 10.1186/s43058-021-00164-3. PubMed 34281614 ↗
  • Galactionova K, Sahu M, Gideon SP, Puthupalayam Kaliappan S, Morozoff C, Ajjampur SSR, Walson J, Rubin Means A, Tediosi F. Costing interventions in the field: preliminary cost estimates and lessons learned from an evaluation of community-wide mass drug administration for elimination of soil-transmitted helminths in the DeWorm3 trial. BMJ Open. 2021 Jul 5;11(7):e049734. doi: 10.1136/bmjopen-2021-049734. PubMed 34226233 ↗
  • Witek-McManus S, Simwanza J, Chisambi AB, Kepha S, Kamwendo Z, Mbwinja A, Samikwa L, Oswald WE, Kennedy DS, Timothy JWS, Legge H, Galagan SR, Emmanuel-Fabula M, Schaer F, Asbjornsdottir K, Halliday KE, Walson JL, Juziwelo L, Bailey RL, Kalua K, Pullan RL. Epidemiology of soil-transmitted helminths following sustained implementation of routine preventive chemotherapy: Demographics and baseline results of a cluster randomised trial in southern Malawi. PLoS Negl Trop Dis. 2021 May 12;15(5):e0009292. doi: 10.1371/journal.pntd.0009292. eCollection 2021 May. PubMed 33979325 ↗
  • Ajjampur SSR, Kaliappan SP, Halliday KE, Palanisamy G, Farzana J, Manuel M, Abraham D, Laxmanan S, Aruldas K, Rose A, Kennedy DS, Oswald WE, Pullan RL, Galagan SR, Asbjornsdottir K, Anderson RM, Muliyil J, Sarkar R, Kang G, Walson JL. Epidemiology of soil transmitted helminths and risk analysis of hookworm infections in the community: Results from the DeWorm3 Trial in southern India. PLoS Negl Trop Dis. 2021 Apr 30;15(4):e0009338. doi: 10.1371/journal.pntd.0009338. eCollection 2021 Apr. PubMed 33930024 ↗
  • DeWorm3 Trials Team. Baseline patterns of infection in regions of Benin, Malawi and India seeking to interrupt transmission of soil transmitted helminths (STH) in the DeWorm3 trial. PLoS Negl Trop Dis. 2020 Nov 2;14(11):e0008771. doi: 10.1371/journal.pntd.0008771. eCollection 2020 Nov. PubMed 33137100 ↗
  • Asbjornsdottir KH, Ajjampur SSR, Anderson RM, Bailey R, Gardiner I, Halliday KE, Ibikounle M, Kalua K, Kang G, Littlewood DTJ, Luty AJF, Means AR, Oswald W, Pullan RL, Sarkar R, Schar F, Szpiro A, Truscott JE, Werkman M, Yard E, Walson JL; DeWorm3 Trials Team. Assessing the feasibility of interrupting the transmission of soil-transmitted helminths through mass drug administration: The DeWorm3 cluster randomized trial protocol. PLoS Negl Trop Dis. 2018 Jan 18;12(1):e0006166. doi: 10.1371/journal.pntd.0006166. eCollection 2018 Jan. PubMed 29346377 ↗

Study documents

  • Study protocol · Jun 15, 2017
  • Statistical analysis plan · Jan 2, 2024

Documents are hosted by the registry — open the source record to download them.

09

Registry details

Key details

Study ID
NCT03014167
Lead sponsor
University of Washington
Collaborators
Bill and Melinda Gates Foundation, Imperial College London, London School of Hygiene and Tropical Medicine, Institut de Recherche Clinique du Benin, Institut de Recherche pour le Developpement, Christian Medical College, Vellore, India, Blantyre Institute for Community Ophthalmology (BICO), Swiss Tropical & Public Health Institute, National Institute of Allergy and Infectious Diseases (NIAID)
Responsible party
Judd Walson (Professor in Departments of Global Health, Medicine (Infectious Disease), Pediatrics and Epidemiology, University of Washington) — Principal investigator
First posted
Jan 9, 2017
Start date
Oct 4, 2017
Primary completion
Jul 2, 2024
Completion
Jul 2, 2024
Results posted
Jan 22, 2026
Last update
Jan 22, 2026

Study contacts

Judd L Walson, MD, MPH
principal investigator · University of Washington, Departments of Global Health, Medicine (Infectious Disease), Pediatrics and Epidemiology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Helminthiasis→

Other studies from this sponsor

University of Washington

Start the discussion